8-K: Zimmer Biomet to Acquire Monogram Technologies, Expanding Orthopedic Robotics with Autonomous Solutions

Zimmer Biomet Holdings, Inc. has entered into a definitive agreement to acquire Monogram Technologies Inc. for an upfront cash payment of $4.04 per share plus contingent value rights, aiming to enhance its orthopedic robotics portfolio with semiand fully autonomous surgical technologies.

Summary

• Monogram Technologies Inc. will be acquired by Zimmer Biomet Holdings, Inc. through its wholly-owned subsidiary, Honey Badger Merger Sub, Inc., becoming a wholly-owned subsidiary of Zimmer Biomet.
• Common stockholders of Monogram will receive $4.04 per share in cash and one non-tradeable Contingent Value Right (CVR) per share.
• Holders of Monogram's 8.00% Series D Convertible Cumulative Preferred Stock will receive $2.25 per share in cash, plus any accrued but unpaid dividends.
• Holders of Monogram's Series E Redeemable Perpetual Preferred Stock will receive $100.00 per share in cash.
• Outstanding stock options will be canceled, with vested portions receiving a cash payment equal to the excess of the $4.04 Cash Amount over the exercise price, plus one CVR. If the exercise price is equal to or greater than the Cash Amount but less than the sum of the Cash Amount and maximum CVR payments, only one CVR will be received, with the CVR payment reduced by the exercise price excess.
• The total equity value of the transaction is approximately $177 million, and the enterprise value is approximately $168 million.
• The CVRs entitle holders to potential cash payments upon the achievement of specific product development, regulatory, and revenue milestones through 2030, totaling up to $12.37 per CVR.
• A delayed draw loan agreement allows Monogram to request up to $15 million from Zimmer, Inc. (a Zimmer Biomet subsidiary) between December 1, 2025, and the End Date, if the merger is not consummated by then. This loan accrues interest at 10.0% per annum (13.0% upon default) and matures on December 1, 2027.
• Certain Monogram stockholders have entered into voting agreements to support the merger and vote against competing proposals.
• The merger is subject to Monogram stockholder approval, expiration or termination of HSR Act waiting periods, and absence of legal restraints, and is not subject to a financing condition.

Sentiment

Score: 8

Explanation: The document presents a highly positive outlook on the acquisition, emphasizing strategic benefits, market leadership potential, and favorable financial projections for the acquirer. While risks are disclosed, they are framed as standard for such transactions, and the overall tone is confident and forward-looking.

Positives

• The acquisition is expected to be neutral to Zimmer Biomet's adjusted earnings per share in 2025-2027 and accretive thereafter, indicating long-term financial benefits.
• The transaction is projected to contribute to Zimmer Biomet's revenue growth starting in 2027.
• Zimmer Biomet anticipates a high-single digit return on invested capital (ROIC) by year five, with increasing contribution thereafter.
• Monogram's CT-based, semi-autonomous, AI-navigated total knee arthroplasty (TKA) robotic technology received FDA 510(k) clearance in March 2025, providing a clear regulatory pathway.
• The acquisition creates a pathway for Zimmer Biomet to potentially become the first company in orthopedics to offer a fully autonomous surgical robot, enhancing its market leadership.
• The CVR structure provides Monogram shareholders with potential upside participation based on future product development, regulatory, and revenue achievements.
• The delayed draw loan agreement provides Monogram with up to $15 million in liquidity if the merger is not consummated by December 1, 2025, ensuring operational continuity.

Negatives

• Monogram is obligated to pay Zimmer Biomet a termination fee of $11 million under certain specified circumstances, such as terminating the agreement to pursue a superior offer or if the Board changes its recommendation.
• The contingent value rights (CVRs) are non-tradeable, limiting liquidity for holders.
• There is no assurance that any of the CVR milestones will be achieved, meaning the full potential CVR payment of $12.37 per share may not be realized.
• The loan agreement includes mandatory prepayment clauses triggered by a change of control, material financings, or entering into an acquisition proposal with a third party, which could limit Monogram's financial flexibility if the merger does not close.

Risks

• Risks related to the satisfaction of closing conditions, including the failure to obtain necessary regulatory approvals (e.g., HSR Act clearance) in the anticipated timeframe or at all.
• Uncertainties regarding whether Monogram's stockholders will approve the proposed transaction.
• The possibility that competing offers or acquisition proposals for Monogram will be made, potentially disrupting the current agreement.
• The occurrence of any event, change, or other circumstances that could give rise to the termination of the Merger Agreement, including situations requiring Monogram to pay a termination fee.
• Risks related to the ability to realize the anticipated benefits of the proposed transaction, including the possibility that expected benefits will not be realized or will not be realized within the expected time period.
• Risks associated with the successful integration of Monogram's business into Zimmer Biomet's operations.
• Risks relating to changing demand for Monogram's existing products.
• Risks relating to the achievement, in part or at all, of the revenue and other milestones necessary for the payment of any contingent value rights.
• Disruption from the proposed transaction making it more difficult to maintain business and operational relationships, including with customers, vendors, service providers, and employees.
• Risks related to the proposed transaction diverting Monogram's management's attention from ongoing business operations.
• Negative effects of the announcement or consummation of the proposed transaction on the market price of Monogram's common stock and on its operating results.
• Significant transaction costs associated with the merger.
• Unknown liabilities that may arise post-acquisition.
• The risk of litigation, including shareholder litigation, and/or regulatory actions, including any conditions, limitations, or restrictions placed on approvals by any applicable governmental entities, related to the proposed transaction.

Future Outlook

Zimmer Biomet expects the acquisition to be neutral to its adjusted earnings per share in 2025, 2026, and 2027, becoming accretive in 2028 and beyond. The transaction is also anticipated to contribute to Zimmer Biomet's revenue growth starting in 2027. Monogram's CT-based, semi-autonomous TKA robotic technology, which received FDA 510(k) clearance in March 2025, is expected to be commercialized with Zimmer Biomet implants in early 2027. Monogram is also developing a fully autonomous version of the technology and additional applications beyond TKA.

Management Comments

• Ivan Tornos, Chairman, President, and CEO of Zimmer Biomet, stated, "Monogram's technology is a major leap forward, demonstrating our commitment to becoming the boldest and broadest innovator in surgical robotics and navigation."
• Tornos also commented, "Upon closing, our customer-centric portfolio will consist of the most comprehensive and flexible technology ecosystem to support the varying preferences of a vast array of surgeons now and into the future."
• Benjamin Sexson, CEO of Monogram, stated, "Since our inception, we have been singularly focused on advancing orthopedic robotics with technology designed to safely, efficiently and accurately support surgeons with total knee arthroplasty."
• Sexson added, "We are thrilled by the opportunity to add our technology to Zimmer Biomet's leading portfolio of surgical robotics, navigation solutions and trusted implants and to benefit from their deep industry expertise and global scale."

Industry Context

This acquisition signifies a strategic move by Zimmer Biomet to solidify its leadership in the rapidly growing orthopedic robotics segment. By integrating Monogram's semiand fully autonomous robotic technologies, Zimmer Biomet aims to expand its flagship ROSA Robotics platform and offer a more comprehensive and flexible technology ecosystem. This positions Zimmer Biomet to address diverse surgeon preferences, including CT and non-CT, robotic and non-robotic, and manual, surgeon-centered, or autonomous surgical techniques, potentially redefining the standard of care in orthopedic surgery.

Comparison to Industry Standards

• Zimmer Biomet's ROSA platform is a market leader outside of the United States and is rapidly approaching 2,000 installations worldwide, indicating a strong existing presence in the surgical robotics market.
• With Monogram's proprietary technology, Zimmer Biomet has the potential to become the first and only company in orthopedics to offer a fully autonomous surgical robot, setting a new benchmark in the industry.
• Zimmer Biomet is investing in a robust R&D pipeline for its ROSA platform, with new product and software applications expected between now and 2027, including ROSA Knee with OptimiZe (FDA submission made, 510(k) clearance anticipated later this year), ROSA Posterior Hip, and the full commercial launch of ROSA Shoulder, demonstrating continuous innovation compared to competitors.

Management Changes

Corporate Governance

Legal Proceedings

• The document notes a risk of litigation, including shareholder litigation, and/or regulatory actions related to the proposed transaction.

Related Party Transactions

• A Voting Agreement was entered into on July 11, 2025, between Parent, Merger Sub, and certain stockholders of Monogram, obligating these stockholders to vote in favor of the merger and against any competing takeover proposals.
• A Delayed Draw Loan Agreement was entered into on July 11, 2025, between Monogram and Zimmer, Inc., a wholly-owned subsidiary of Parent, providing Monogram with access to up to $15 million in loans under specific conditions if the merger is not consummated by December 1, 2025.

Stakeholder Impact

• Shareholders: Common stockholders receive cash and CVRs, providing immediate value and potential future upside. Preferred stockholders receive cash payments. The CVRs are non-tradeable, limiting liquidity for this portion of the consideration.
• Employees: Key employees are executing employment agreements or offer letters and restrictive covenant agreements with Parent/Affiliates, effective at the Effective Time, indicating retention efforts. Parent commits to providing comparable compensation and benefits for one year post-closing for continuing employees.
• Customers: The acquisition is expected to expand Zimmer Biomet's portfolio, offering a broader range of robotic and navigation technologies to meet varying surgeon needs.
• Suppliers/Vendors: The transaction may disrupt existing business and operational relationships, as noted in the risks section.
• Regulatory Authorities: The transaction is subject to regulatory approvals, particularly under Antitrust Laws and FDA clearances for Monogram's products, which could impact the timeline and terms of the closing.

Next Steps

• Obtain Monogram's common stockholder approval for the merger.
• Secure required regulatory approvals, including the expiration or termination of waiting periods under the Hart-Scott-Rodino Antitrust Improvements Act.
• Complete the merger, anticipated to close later this year.
• Commercialize Monogram's CT-based, semi-autonomous TKA robotic technology with Zimmer Biomet implants in early 2027.
• Continue advancing Zimmer Biomet's ROSA platform, including anticipated FDA 510(k) clearance for ROSA Knee with OptimiZe later this year, and full commercial launches of ROSA Posterior Hip and ROSA Shoulder.
• Achieve CVR milestones related to product development, regulatory clearance, and revenue targets through 2030 to trigger contingent payments.

Key Dates

Recommendation

Keywords

Orthopedic Robotics, Medical Technology, Acquisition, AI-driven Robotics, Knee Arthroplasty, Surgical Robotics, Contingent Value Rights, Merger Agreement, FDA Clearance, Zimmer Biomet, Monogram Technologies